Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
India
/
Pharmaceuticals & Biotech
/
Blue Jet Healthcare
BLUEJET
Blue Jet Healthcare
Escalating Regulatory And Supply Risks Will Weaken Outlook
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 6 Analysts
Published
15 Jul 25
Updated
24 Jul 25
0
Set Fair Value
0
votes
Share
AnalystLowTarget
's Fair Value
₹730.00
6.2% overvalued
intrinsic discount
24 Jul
₹775.35
Loading
1Y
64.0%
7D
-1.7%
Author's Valuation
₹730.0
6.2% overvalued
intrinsic discount
AnalystLowTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystLowTarget Fair Value
₹730.0
6.2% overvalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
0
18b
2020
2021
2022
2023
2024
2025
2026
2027
2028
Revenue ₹17.8b
Earnings ₹5.1b
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
16.95%
Pharma revenue growth rate
0.58%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
12.73%
Calculation
₹5.15b
Earnings '28
x
34.97x
PE Ratio '28
=
₹180.05b
Market Cap '28
₹180.05b
Market Cap '28
/
173.44m
No. shares '28
=
₹1.04k
Share Price '28
₹1.04k
Share Price '28
Discounted to 2025 @ 12.55% p.a.
=
₹728.14
Fair Value '25
